HIF-2α depletion and inhibition suppresses VHL null ccRCC progression [58–60], and HIF-2 inhibitors are now in clinical use for advanced-stage ccRCC and VHL disease [61,62]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.